Paxneury 1 mg prolonged-release tablets
Authorisation EU/1/24/1908/001 · Neuraxpharm Pharmaceuticals S.L.
- Licence holder
- Neuraxpharm Pharmaceuticals S.L. (all products →)
- Active substance
- Guanfacine hydrochloride
- Dosage form
- Prolonged-release tablet
- Route of administration
- Oral use
- ATC code
- C02AC02
- First authorised
- 26/02/2025
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Hybrid application (Article 10(3) of Directive No 2001/83/EC)
Guanfacine hydrochloride: supply and approvals
11 authorised products on the HPRA list contain Guanfacine hydrochloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
- No entry in the EMA shortage catalogue (checked 18 Nov 2026)
- US shortage (FDA)
- No entry in the FDA drug shortage list (checked 18 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 18 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 1908. It has been authorised for 1 year (since 26 February 2025). The HPRA list does not say whether it is on sale.
Other medicines with Guanfacine hydrochloride in Ireland
10 other products on the HPRA list contain Guanfacine hydrochloride, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Intuniv 1 mg prolonged-release tablets | Takeda Pharmaceuticals International AG Ireland Branch | Centralised EU authorisation | Not stated |
| Intuniv 2 mg prolonged-release tablets | Takeda Pharmaceuticals International AG Ireland Branch | Centralised EU authorisation | Not stated |
| Intuniv 3 mg prolonged-release tablets | Takeda Pharmaceuticals International AG Ireland Branch | Centralised EU authorisation | Not stated |
| Intuniv 4 mg prolonged-release tablets | Takeda Pharmaceuticals International AG Ireland Branch | Centralised EU authorisation | Not stated |
| Paxneury 2 mg prolonged-release tablets | Neuraxpharm Pharmaceuticals S.L. | Centralised EU authorisation | Not stated |
| Paxneury 3 mg prolonged-release tablets | Neuraxpharm Pharmaceuticals S.L. | Centralised EU authorisation | Not stated |
| Paxneury 4 mg prolonged-release tablets | Neuraxpharm Pharmaceuticals S.L. | Centralised EU authorisation | Not stated |
| Paxneury 5 mg prolonged-release tablets | Neuraxpharm Pharmaceuticals S.L. | Centralised EU authorisation | Not stated |
| Paxneury 6 mg prolonged-release tablets | Neuraxpharm Pharmaceuticals S.L. | Centralised EU authorisation | Not stated |
| Paxneury 7 mg prolonged-release tablets | Neuraxpharm Pharmaceuticals S.L. | Centralised EU authorisation | Not stated |
The licence holder
Neuraxpharm Pharmaceuticals S.L. holds 23 products on the HPRA list, with 7 different active substances; 2 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.